Jefferies Group Reaffirms “Buy” Rating for Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (NASDAQ:VNDA)‘s stock had its “buy” rating reaffirmed by analysts at Jefferies Group in a research report issued on Tuesday. They currently have a $20.00 target price on the biopharmaceutical company’s stock. Jefferies Group’s price objective would indicate a potential upside of 28.21% from the company’s current price.

A number of other brokerages also recently issued reports on VNDA. Zacks Investment Research upgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a research report on Wednesday, October 18th. Piper Jaffray Companies set a $26.00 price target on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, October 19th. Oppenheimer restated a “buy” rating on shares of Vanda Pharmaceuticals in a research report on Monday, January 8th. BidaskClub upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, December 22nd. Finally, ValuEngine upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, December 20th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $21.14.

Shares of Vanda Pharmaceuticals (VNDA) traded down $0.02 during midday trading on Tuesday, hitting $15.60. 411,400 shares of the stock were exchanged, compared to its average volume of 547,670. The firm has a market cap of $701.99, a P/E ratio of -50.32 and a beta of 1.24. Vanda Pharmaceuticals has a 1 year low of $11.90 and a 1 year high of $18.99.

In other news, insider Mihael Hristos Polymeropoulos sold 191,760 shares of Vanda Pharmaceuticals stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $15.30, for a total value of $2,933,928.00. Following the completion of the sale, the insider now owns 1,031,848 shares in the company, valued at approximately $15,787,274.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Gunther Birznieks sold 8,568 shares of Vanda Pharmaceuticals stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $15.26, for a total transaction of $130,747.68. Following the completion of the sale, the senior vice president now owns 118,366 shares of the company’s stock, valued at approximately $1,806,265.16. The disclosure for this sale can be found here. Insiders sold a total of 209,483 shares of company stock valued at $3,205,205 in the last quarter. 7.60% of the stock is currently owned by company insiders.

Several large investors have recently added to or reduced their stakes in VNDA. Rothschild Asset Management Inc. bought a new stake in shares of Vanda Pharmaceuticals in the 3rd quarter valued at $23,491,000. Sei Investments Co. increased its stake in shares of Vanda Pharmaceuticals by 15,516.7% in the 3rd quarter. Sei Investments Co. now owns 267,671 shares of the biopharmaceutical company’s stock valued at $4,792,000 after acquiring an additional 265,957 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Vanda Pharmaceuticals by 7.5% in the 2nd quarter. Vanguard Group Inc. now owns 2,680,895 shares of the biopharmaceutical company’s stock valued at $43,698,000 after acquiring an additional 186,548 shares in the last quarter. Macquarie Group Ltd. increased its stake in shares of Vanda Pharmaceuticals by 10.9% in the 3rd quarter. Macquarie Group Ltd. now owns 1,890,085 shares of the biopharmaceutical company’s stock valued at $33,833,000 after acquiring an additional 186,526 shares in the last quarter. Finally, Cortina Asset Management LLC increased its stake in shares of Vanda Pharmaceuticals by 81.9% in the 4th quarter. Cortina Asset Management LLC now owns 386,477 shares of the biopharmaceutical company’s stock valued at $5,874,000 after acquiring an additional 173,974 shares in the last quarter. Institutional investors own 88.19% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Jefferies Group Reaffirms “Buy” Rating for Vanda Pharmaceuticals (VNDA)” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/02/13/jefferies-group-reaffirms-buy-rating-for-vanda-pharmaceuticals-vnda.html.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply